EIGR earnings

Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor

Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at

Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV. The live and replayed webcast of the call will be available through the company's websi

Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in DecemberPhase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling PatientsPhase 3 Congenital Hyperinsulinism Avant (avexitide) Program InitiatedStrong Cash Position: $121.0 Million in Cash, Cash Equivalents, and Total InvestmentsPALO ALTO, Calif., Nov. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for third quarter 2022 and provided a business update.

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website at www.eig

Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA ApplicationPhase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year EndPhase 3 Congenital Hyperinsulinism AVANT (avexitide) Program InitiatedApproval of Zokinvy in Europe; Partnership with AnGes in JapanStrong Cash Position: $141.8M Cash, Cash Equivalents, and Total InvestmentsPALO ALTO, Calif., Aug. 4, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) infection and other serious diseases, today reported financial results for second quarter 2022 and provided a business

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, August 4, 2022 at 4:30 PM ET to discuss its second quarter 2022 financial results and provide a business update.  The live and replayed webcast of the call will be available through the company's website at www.eig

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year EndZokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year EndStrong Cash Position: $153.5M Pro Forma CashPALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2022 and provided a business update.

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website

Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron Eiger plans to submit data to FDA for Emergency Use Authorization (EUA) Management to host conference call today at 8:30 AM ET PALO ALTO, Calif., March 17, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announce

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern, to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19. The live and replayed webcast of

PALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 Phase 3 HDV LIMT-2 (Lambda) Study Enrolling Strong Cash Position of Approximately $106 Million as of 12/31/21 Company to Host Conference Call Today at 4:30 PM ETEiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today reported financ

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 10, 2022 at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com.  To participat

PALO ALTO, Calif., Nov. 4, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today reported its third quarter 2021 financial results and provided a business update. "The recent completion of enrollment in our Phase 3 HDV D-LIVR study of Lonafarnib-based regimens sets up pivotal topline data by the end of 2022," said David Cory, President and CEO.  "Additionally, our Phase 3 HDV LIMT-2 stu

PALO ALTO, Calif., Oct. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, November 4, 2021 at 4:30 PM ET to discuss its financial results and provide a business update for the third quarter 2021. The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com.  To participate in the live call

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its second quarter 2021 financial results and provided a business update. "Our rapidly advancing HDV platform strategy, which includes Lonafarnib and Peginterferon Lambda, provides multiple opportunities to deliver a win for HDV patients and positions us to be a leader in this space," said David Cory, President and

PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, August 5, 2021 at 4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021. The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call b